Skip to Main Content

Most-read Content of September: Using risk scores to improve patient outcomes, dual antiplatelet therapy, and more

October 06, 2022
by Elisabeth Reitman

The most-read articles of September 2022 included the REVEAL-HF trial, optimal dual antiplatelet therapy (DAPT) duration, and the impact of the COVID-19 pandemic on productivity and stress-levels.

September 2022 Research Summary:

Clinical Outcomes and Cost Associated With an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump in Patients Presenting With Acute Myocardial Infarction Complicated by Cardiogenic Shock

A propensity-matched analysis underscores the need for optimal management of patients undergoing PCI for a heart attack or acute myocardial infarction.

Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure

The REVeAL-HF (Risk Evaluation and its Impact on Clinical Decision Making and Outcomes in Heart Failure) trial assessed whether provision of mortality estimates impacted clinical decision-making and outcomes in hospitalized patients with heart failure. The results appear in JAMA Cardiology.

The Impact of COVID-19 on Physician Scientist Trainees and Faculty in the United States: A National Survey

With the support of the American Physician Scientists Association (APSA), researchers conducted a national survey of more than 2,000 physician-scientist trainees and faculty.

Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis

In this systematic review and meta-analysis, researchers investigated the effects of using DAPT for 1 to 3 months compared with 6 to 12 months to prevent ischemia.

Submitted by Elisabeth Reitman on October 05, 2022